On November 3, Hims & Hers Health Inc. fell 5.22% in Regular Trading, trading at $26.2201 per share, with turnover of $178 million.
The move coincided with continued market focus on the company’s effort to dismiss a Federal Trade Commission complaint alleging it misled consumers about products and billed for unwanted subscriptions, a compliance issue that has continued to pressure risk appetite.
Recent disclosures show the company asked a California federal judge to throw out the FTC case, but the dispute remains unresolved. Separately, its weight-loss subscription business was reported to have faced a surge in credit-card disputes, leading to notice under Visa’s monitoring program and nearly $75,000 in related charges. With the next earnings report due on November 9 and consensus expecting quarterly revenue of $893 million, investors appear to be weighing strong top-line growth against ongoing regulatory and billing-related risks.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments